Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
MWN-AI** Summary
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotech company focused on integrin-based therapeutics, provided a corporate update along with its financial results for the third quarter of 2025 on November 6, 2025. The company reported significant advances in its oncology program, particularly with its lead drug candidate, PLN-101095, which has completed enrollment for its Phase 1 open-label trial in patients with solid tumors resistant to immune checkpoint inhibitors. Interim data released indicated that the treatment was well tolerated, achieving a 50% objective response rate in one cohort. Full data from this trial is expected in the fourth quarter of 2025.
Pliant has also been winding down activities related to the BEACON-IPF trial, which investigated Bexotegrast for idiopathic pulmonary fibrosis, with close-out activities projected to finish by the end of the fourth quarter.
Financially, Pliant reported a net loss of $26.3 million for Q3 2025, a substantial decrease from the $57.8 million loss recorded in the same period the previous year. This reduction in loss was mainly attributed to the discontinuation of BEACON-IPF and a strategic restructuring that led to reduced general and administrative expenses, which were cut to $10.3 million from $14.3 million year-over-year. Research and development expenses dropped to $17.9 million, down from $47.8 million, reflecting a focus on streamlining operations.
As of September 30, 2025, Pliant held approximately $243.3 million in cash and investments, providing a solid financial foundation for ongoing and upcoming projects. CEO Bernard Coulie emphasized the company's commitment to creating shareholder value through continued innovation and evaluation of strategic opportunities.
MWN-AI** Analysis
Pliant Therapeutics, Inc. (Nasdaq: PLRX) has provided an update that signals a pivotal moment for the company as it transitions from the BEACON-IPF program to its oncology initiatives. The reported third-quarter financial results reveal a hefty reduction in operational losses and R&D expenses, primarily attributed to the winding down of the BEACON-IPF trial.
Key developments include the completion of enrollment for the Phase 1 trial of PLN-101095, an oral dual-selective integrin inhibitor. Positive interim data, showcasing a 50% objective response rate presented in earlier cohorts, adds credence to the drug’s potential, particularly in overcoming immune checkpoint resistance. With full data anticipated by year-end, investor sentiment may positively shift, contingent on favorable outcomes.
Financially, Pliant's net loss dropped to $26.3 million from $57.8 million year-over-year, indicating a prudent management strategy as reflected in decreased general and administrative costs due to workforce restructuring. The company's current cash position stands strong at $243.3 million, providing a runway to potentially capitalize on the clinical results anticipated later this quarter, along with supporting operational flexibility going forward.
However, caution is warranted. The upcoming data readout from the PLN-101095 trial will be critical; success is imperative for boosting market confidence and validating Pliant's strategic pivot towards oncology. As Pliant has successfully navigated its financial commitments, including a significant loan prepayment, it underscores a focus on fiscal health while moving towards groundbreaking therapeutic avenues.
Investors should watch for the data release and any subsequent analyst commentary closely. Short-term volatility can be expected leading up to these results, and a favorable outcome may represent a compelling entry for long-term holders. Conversely, any negative data could lead to rapid sell-off; therefore, risk-reward dynamics should be carefully assessed.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Oncology program advancing with data expected in the fourth quarter 2025
BEACON-IPF close out activities to be completed in the fourth quarter 2025
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported third quarter 2025 financial results.
“During the third quarter, our team continued to advance our portfolio while winding down activities surrounding the BEACON-IPF trial,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “Looking ahead, we continue to evaluate a range of opportunities to create shareholder value.”
Third Quarter and Recent Developments
Oncology Program
- Phase 1 open-label trial of PLN-101095 in solid tumors has completed enrollment . PLN-101095 is an oral, small molecule, dual selective inhibitor of ?v?8 and ?v?1 integrins designed to overcome checkpoint resistance by blocking TGF-? activation in the tumor microenvironment. The Phase 1 open-label, dose-escalation trial of PLN-101095 as monotherapy and in combination with pembrolizumab is in patients with solid tumors that are resistant to immune checkpoint inhibitors. In March of 2025 we announced interim data from this trial showing PLN-101095 was well tolerated and displayed an objective response rate of 50% in the third of five ascending dose cohorts. The trial has now completed enrollment of all five dose cohorts. Data from the trial, including the two highest dose cohorts, is expected by the end of 2025.
Bexotegrast
- BEACON-IPF close out activities to be completed in fourth quarter. Close out activities from the BEACON-IPF Phase 2b/3 clinical trial are expected to be completed in the fourth quarter of 2025 with full results from the trial to be submitted for future publication.
Corporate Highlights
- In October, the Company announced that it completed a voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs and expenses under the March 11, 2024 Loan Agreement with Oxford Finance LLC.
Third Quarter 2025 Financial Results
- Research and development expenses were $17.9 million as compared to $47.8 million for the prior-year quarter. The decrease was primarily driven by the discontinuation of BEACON-IPF.
- General and administrative expenses were $10.3 million as compared to $14.3 million for the prior-year quarter. The decrease was primarily due to lower personnel-related costs resulting from the strategic restructuring of our workforce.
- Net loss was $26.3 million as compared to $57.8 million for the prior-year quarter. The decrease was primarily attributable to the discontinuation of BEACON-IPF coupled with the decrease in personnel-related costs resulting from the strategic restructuring of our workforce.
- As of September 30, 2025, the Company had cash, cash equivalents and short-term investments of $243.3 million.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of ? v ß 8 and ? v ß 1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin ? 7 ? 1 targeting muscular dystrophies. Pliant’s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com . Follow us on social media X , LinkedIn and Facebook .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding the close-out of the BEACON-IPF study, the anticipated timing of data from our ongoing Phase 1 trial of PLN-101095, the cost savings expected to result from our strategic restructuring, our ongoing evaluation of business opportunities and our ability to maintain core capabilities in support of Pliant’s next steps. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic, geopolitical and marketplace conditions on our business, operations, clinical supply and plans, our reliance on single-source third parties located in foreign jurisdictions, including China, for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the period ended September 30, 2025 which we are filing with the SEC today, available on the SEC's website at www.sec.gov. Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
| Pliant Therapeutics, Inc. Condensed Statements of Operations (Unaudited) (In thousands, except number of shares and per share amounts) | |||||||
| Three Months Ended September 30, | |||||||
| 2025 | 2024 | ||||||
| Operating expenses: | |||||||
| Research and development | $ | (17,938 | ) | $ | (47,754 | ) | |
| General and administrative | (10,331 | ) | (14,260 | ) | |||
| Total operating expenses | (28,269 | ) | (62,014 | ) | |||
| Loss from operations | (28,269 | ) | (62,014 | ) | |||
| Interest and other income (expense), net | 2,783 | 5,128 | |||||
| Interest expense | (815 | ) | (877 | ) | |||
| Net loss | $ | (26,301 | ) | $ | (57,763 | ) | |
| Net loss per share - basic and diluted | $ | (0.43 | ) | $ | (0.95 | ) | |
| Shares used in computing net loss per share - basic and diluted | 61,406,475 | 60,730,935 | |||||
| Pliant Therapeutics, Inc. Condensed Balance Sheets (Unaudited) (In thousands) | |||||||
| September 30, 2025 | December 31, 2024 | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 93,732 | $ | 71,188 | |||
| Short-term investments | 148,065 | 284,536 | |||||
| Prepaid expenses and other current assets | 3,791 | 6,540 | |||||
| Total current assets | 245,588 | 362,264 | |||||
| Property and equipment, net | 4,344 | 5,525 | |||||
| Operating lease right-of-use assets | 24,794 | 27,243 | |||||
| Restricted cash | 1,482 | 1,482 | |||||
| Other non-current assets | 392 | 435 | |||||
| Total assets | $ | 276,600 | $ | 396,949 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 485 | $ | 5,960 | |||
| Accrued research and development | 7,779 | 14,363 | |||||
| Accrued liabilities | 8,173 | 12,353 | |||||
| Operating lease liabilities, current | 1,187 | 542 | |||||
| Total current liabilities | 17,624 | 33,218 | |||||
| Operating lease liabilities, non-current | 28,231 | 29,439 | |||||
| Long-term debt | 30,439 | 30,211 | |||||
| Total liabilities | 76,294 | 92,868 | |||||
| Stockholders’ equity | |||||||
| Preferred stock | — | — | |||||
| Common stock | 6 | 6 | |||||
| Additional paid-in capital | 1,036,085 | 1,013,806 | |||||
| Accumulated deficit | (835,819 | ) | (710,052 | ) | |||
| Accumulated other comprehensive gain | 34 | 321 | |||||
| Total stockholders’ equity | 200,306 | 304,081 | |||||
| Total liabilities and stockholders’ equity | $ | 276,600 | $ | 396,949 | |||
FAQ**
What specific data should investors anticipate from Pliant Therapeutics Inc. (Nasdaq: PLRX) regarding the Phase 1 trial of PLN-101095 in solid tumors by the end of 2025?
How does the completion of BEACON-IPF close-out activities in Q4 20impact the potential future direction of Pliant Therapeutics Inc. (PLRX)?
What strategies is Pliant Therapeutics Inc. (PLRX) considering to create shareholder value following the discontinuation of the BEACON-IPF trial?
With the reported interim data showing a 50% response rate for PLN-101095, what are the next steps for Pliant Therapeutics Inc. (Nasdaq: PLRX) in advancing this oncology program?
**MWN-AI FAQ is based on asking OpenAI questions about Pliant Therapeutics Inc. (NASDAQ: PLRX).
NASDAQ: PLRX
PLRX Trading
-3.21% G/L:
$1.355 Last:
63,435 Volume:
$1.37 Open:
